SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (791)9/27/1998 1:00:00 PM
From: FNS  Read Replies (1) | Respond to of 965
 
Peter: <<... and the ReoPro/Retavase combination becomes the standard therapy for MI...>> I think you got it RIGHT!

Further, IMHO CNTO has to build up their pipeline of drugs to stay mainstream in the cardio area and play catch up in the RA area.

The anticipated positive tone of the market for next week and Oct earnings around the corner should help the stock near term...I wouldn't want to be short the bio sector at this time.

FNS